Lunai Bioworks Stock (NASDAQ:RENB)

Ownership Financials Chart

Previous Close

$1.42

52W Range

$1.12 - $21.00

50D Avg

$1.96

200D Avg

$4.41

Market Cap

$32.92M

Avg Vol (3M)

$218.51K

Beta

0.53

Div Yield

-

RENB Company Profile

Lunai Bioworks, Inc. is a pre-clinical stage biotechnology company, which engages in the development of genetically modified cellular and immune-therapy technologies used for the treatment of infectious diseases and cancer. Its pipeline consists of ENOB-HV-01, ENOB- HV-11, ENOB-HV-12, ENOB-DB-01, ENOB-DC-01, ENOB-DC-11, and ENOB-DC-21. The company was founded by Rene Sindlev and Serhat Gumrukcu on January 18, 2011 and is headquartered in Los Angeles, CA.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

25

IPO Date

Feb 07, 2018

Website

RENB Performance

RENB Financial Summary

	Jun 24	Jun 23	Jun 22
Revenue	-	-	-
Operating Income	$-81.64M	$-38.56M	$-116.08M
Net Income	$-80.65M	$-39.68M	$-113.43M
EBITDA	$-81.52M	$-19.48M	$-22.70M
Basic EPS	$-8.40	$-7.10	$-21.60
Diluted EPS	$-8.40	$-7.10	$-21.60

Fiscal year ends in Jun 24 | Currency in USD

Peer Comparison

Ticker	Company
IRD	Opus Genetics, Inc.
MRNS	Marinus Pharmaceuticals, Inc.
ALLK	Allakos Inc.
GRCE	Grace Therapeutics, Inc.
ORKA	Oruka Therapeutics, Inc.